

**Biosimilars Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)**

Market Report | 2023-02-24 | 217 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$4550.00
- Site Price \$6550.00
- Enterprise Price \$8550.00

**Report description:**

The biosimilars market was valued at US\$ 18,435.89 million in 2021 and is expected to reach US\$ 136,069.53 million by 2028; it is estimated to record a CAGR of 34.8% from 2022 to 2028.

The biosimilars market growth is attributed to the increasing prevalence of chronic diseases, the cost-effectiveness of biosimilar drugs, and the increase in approvals of biosimilars. However, high-cost involvement and complexities in biosimilar product manufacturing restrain the biosimilars market growth.

The Food and Drug Administration (FDA) approves biosimilar products and provides the scientific and regulatory advice needed to bring safe and effective biosimilars to market. The approval of biosimilar products can improve patient care by increasing the number of medication options at potentially lower costs.

A few recent approvals of biosimilar products are mentioned in the following table.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Thus, the rising approvals of biosimilars are propelling the biosimilars market growth.

Collaborations of Market Players for Biosimilar Production and Clinical Trials to Fuel Biosimilar Market Growth During Forecast Period.

Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.

By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.

Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.

There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.

The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:

In January 2022, Samsung Biologics and Biogen entered a joint venture, forming Samsung Bioepis. Samsung Bioepis launched biosimilars of etanercept, adalimumab, infliximab, and trastuzumab in Europe, with others in the pipeline. It has also entered into many commercialization partnerships.

In March 2021, The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP), in collaboration with Pfizer Inc. to launch ten projects, announced that it had received funding to support innovative approaches to enhance the processes related to appropriate biosimilar adoption in oncology.

In September 2019, Henlius announced a strategic collaboration with Ascentage Pharma to conduct clinical trials of the combination therapy between Rituximab Injection, the first launched product by Henlius, and APG-2575, a novel and orally administered Bcl-2 selective inhibitor developed by Ascentage Pharma, for the treatment of chronic lymphocytic leukemia (CLL) in China.

In June 2019, STADA and Xbrane Biopharma expanded their biosimilar collaboration to evaluate potential collaboration on additional products. The two companies stated that they will focus on biosimilars of originator products that will face patent expiry from 2025 to 2030.

Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.

Disease Indication-Based Insights

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2021. The market for the autoimmune diseases segment is likely to grow at the highest rate during the forecast period.

#### Drug Class-Based Insights

The biosimilars market, based on drug class, is segmented into Granulocyte Colony-stimulating Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-stimulating Stimulating Agents, and Others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2021 and is expected to register the highest CAGR of 35.8% during the forecast period.

#### Route of Administration -Based Insights

Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2021 and is expected to register the highest CAGR of 36.0% during the forecast period.

#### End User-Based Insights

The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2021, whereas the homecare segment is expected to register the highest CAGR of 36.6% during the forecast period.

World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Library of Medicine, National Psoriasis Foundation, Statistisches Bundesamt (Destatis), International Diabetes Federation (IDF), and Cardinal Health are a few of the major primary and secondary sources referred to while preparing the report on the biosimilars market.

#### **Table of Contents:**

##### TABLE OF CONTENTS

1. Introduction	30
1.1 Scope of the Study.	30
1.2 The Insight Partners Research Report Guidance.	30
1.3 Market Segmentation.	31
1.3.1 Global Biosimilars Market - by Disease Indication.	33
1.3.2 Global Biosimilars Market - by Drug class.	33
1.3.3 Global Biosimilars Market - by Route of Administration.	33
1.3.4 Global Biosimilars Market - by End User	33
1.3.5 Global Biosimilars Market - by Geography.	33
2. Biosimilars Market - Key Takeaways	35
3. Research Methodology	42
3.1 Coverage.	43
3.2 Secondary Research.	43
3.3 Primary Research.	43
4. Biosimilars Market - Market Landscape	45
4.1 Overview..	45
4.2 PEST Analysis.	45

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.2.1 North America PEST Analysis.	45
4.2.2 Europe PEST Analysis.	46
4.2.3 Asia Pacific PEST Analysis.	46
4.2.4 South & Central America PEST Analysis.	47
4.2.5 Middle East & Africa PEST Analysis.	47
4.3 Expert's Opinion.	48
5. Biosimilars Market - Key Market Dynamics	49
5.1 Market Drivers.	49
5.1.1 Increasing Prevalence of Chronic Diseases.	49
5.1.2 Cost Effectiveness of Biosimilar Drugs.	49
5.1.3 Rising Approvals of Biosimilars.	50
5.2 Market Restraints.	51
5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing.	51
5.3 Market Opportunities.	52
5.3.1 Patent Expiry of Blockbuster Biologics.	52
5.4 Future Trend.	53
5.4.1 Collaborations for Biosimilars and Clinical Trials.	53
5.5 Impact analysis.	54
6. Biosimilars Market - Global Analysis	55
6.1 Global Biosimilars Market Revenue Forecast and Analysis.	55
6.2 Global Biosimilars Market, by Geography - Forecast and Analysis.	56
6.3 Market Positioning of Key Players.	57
7. Global Biosimilars Market - Revenue and Forecast to 2028 - by Disease Indication	58
7.1 Overview..	58
7.2 Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)	58
7.3 Cancer	59
7.3.1 Overview..	59
7.3.2 Cancer: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	59
7.4 Diabetes.	60
7.4.1 Overview..	60
7.4.2 Diabetes: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	60
7.5 Autoimmune Diseases.	61
7.5.1 Overview..	61
7.5.2 Autoimmune Diseases: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	61
7.5.3 Psoriasis:	62
7.5.3.1 Overview..	62
7.5.3.2 Psoriasis: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	62
7.5.4 Arthritis:	63
7.5.4.1 Overview..	63
7.5.4.2 Arthritis: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	63
7.5.5 Others:	64
7.5.5.1 Overview..	64
7.5.5.2 Others: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	64
7.6 Others Disease Indications.	65
7.6.1 Overview..	65
7.6.2 Others Disease Indications: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	65
8. Global Biosimilars Market Analysis and Forecasts to 2028 - by Route of Administration	66

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.1 Overview..	66
8.2 Global Biosimilars Market, by Application 2021 & 2028 (%)	66
8.3 Intravenous.	67
8.3.1 Overview..	67
8.3.2 Intravenous: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	67
8.4 Subcutaneous.	68
8.4.1 Overview..	68
8.4.2 Subcutaneous: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	68
8.5 Others.	69
8.5.1 Overview..	69
8.5.2 Others: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	69
9. Global Biosimilars Market - Revenue and Forecast to 2028 - by End User	70
9.1 Overview..	70
9.2 Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)	70
9.3 Hospitals.	71
9.3.1 Overview..	71
9.3.2 Hospitals: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	71
9.4 Specialty Clinics.	72
9.4.1 Overview..	72
9.4.2 Specialty Clinics: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	72
9.5 Homecare.	73
9.5.1 Overview..	73
9.5.2 Homecare: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	73
9.6 Other	74
9.6.1 Overview..	74
9.6.2 Other: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	74
10. Biosimilars Market - Revenue and Forecast to 2028 - Geographic Analysis	75
10.1 North America: Biosimilar Market Europe.	75
10.1.1 Overview..	75
10.1.2 North America: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	76
10.1.3 North America: Biosimilar Market, by Disease Indication, 2019-2028 (US\$ Million)	76
10.1.3.1 North America: Biosimilar Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	77
10.1.4 North America: Biosimilar Market, by Drug Class, 2019-2028 (US\$ Million)	77
10.1.5 North America: Biosimilar Market, by Route of Administration, 2019-2028 (US\$ Million)	78
10.1.6 North America: Biosimilar Market, by End User, 2019-2028 (US\$ Million)	78
10.1.7 North America: Biosimilar Market, by Country, 2021 & 2028 (%)	79
10.1.7.1 US: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	79
10.1.7.1.1 Overview..	79
10.1.7.1.2 US: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	80
10.1.7.1.3 US: Biosimilar Market, by Disease Indication, 2019-2028 (US\$ Million)	80
10.1.7.1.3.1 US: Biosimilar Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	81
10.1.7.1.4 US: Biosimilar Market, by Drug Class, 2019-2028 (US\$ Million)	81
10.1.7.1.5 US: Biosimilar Market, by Route of Administration, 2019-2028 (US\$ Million)	82
10.1.7.1.6 US: Biosimilar Market, by End User, 2019-2028 (US\$ Million)	82
10.1.7.2 Canada: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	83
10.1.7.2.1 Canada: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	83
10.1.7.2.2 Canada: Biosimilar Market, by Disease Indication, 2019-2028 (US\$ Million)	84

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

10.1.7.2.2.1 Canada: Biosimilar Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	84
10.1.7.2.3 Canada: Biosimilar Market, by Drug Class, 2019-2028 (US\$ Million)	85
10.1.7.2.4 Canada: Biosimilar Market, by Route of Administration, 2019-2028 (US\$ Million)	85
10.1.7.2.5 Canada: Biosimilar Market, by End User, 2019-2028 (US\$ Million)	86
10.1.7.3 Mexico: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	87
10.1.7.3.1 Mexico: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	87
10.1.7.3.2 Mexico: Biosimilar Market, by Disease Indication, 2019-2028 (US\$ Million)	88
10.1.7.3.2.1 Mexico: Biosimilar Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	88
10.1.7.3.3 Mexico: Biosimilar Market, by Drug Class, 2019-2028 (US\$ Million)	88
10.1.7.3.4 Mexico: Biosimilar Market, by Route of Administration, 2019-2028 (US\$ Million)	89
10.1.7.3.5 Mexico: Biosimilar Market, by End User, 2019-2028 (US\$ Million)	89
10.2 Europe: Biosimilars Market	90
10.2.1 Overview..	90
10.2.2 Europe: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	91
10.2.3 Europe: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	91
10.2.3.1 Europe: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	92
10.2.4 Europe: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	92
10.2.5 Europe: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	92
10.2.6 Europe: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	93
10.2.7 Europe: Biosimilars Market, by Country, 2021 & 2028 (%)	93
10.2.7.1 Germany: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	94
10.2.7.1.1 Overview..	94
10.2.7.1.2 Germany: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	94
10.2.7.1.3 Germany: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	95
10.2.7.1.3.1 Germany: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	95
10.2.7.1.4 Germany: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	96
10.2.7.1.5 Germany: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	96
10.2.7.1.6 Germany Biosimilars Market, by End User, 2019-2028 (US\$ Million)	96
10.2.7.2 UK: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	97
10.2.7.2.1 Overview..	97
10.2.7.2.2 UK: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	97
10.2.7.2.3 UK: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	98
10.2.7.2.3.1 UK: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	98
10.2.7.2.4 UK: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	99
10.2.7.2.5 UK: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	99
10.2.7.2.6 UK: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	100
10.2.7.3 France: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	101
10.2.7.3.1 Overview..	101
10.2.7.3.2 France: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	101
10.2.7.3.3 France: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	102
10.2.7.3.3.1 France: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	102
10.2.7.3.4 France: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	102
10.2.7.3.5 France: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	103
10.2.7.3.6 France: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	103
10.2.7.4 Italy: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	104
10.2.7.4.1 Overview..	104
10.2.7.4.2 Italy: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	104

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.2.7.4.3 Italy: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	105
10.2.7.4.3.1 Italy: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	105
10.2.7.4.4 Italy: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	105
10.2.7.4.5 Italy: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	106
10.2.7.4.6 Italy: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	106
10.2.7.5 Spain: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	107
10.2.7.5.1 Overview..	107
10.2.7.5.2 Spain: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	107
10.2.7.5.3 Spain: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	108
10.2.7.5.3.1 Spain: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	109
10.2.7.5.4 Spain: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	109
10.2.7.5.5 Spain: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	109
10.2.7.5.6 Spain: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	110
10.2.7.6 Rest of Europe: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	111
10.2.7.6.1 Overview..	111
10.2.7.6.2 Rest of Europe: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	111
10.2.7.6.3 Rest of Europe: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	112
10.2.7.6.3.1 Rest of Europe: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	112
10.2.7.6.4 Rest of Europe: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	112
10.2.7.6.5 Rest of Europe: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	113
10.2.7.6.6 Rest of Europe: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	113
10.3 Asia Pacific: Biosimilars Market	114
10.3.1 Overview..	114
10.3.2 Asia Pacific: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	115
10.3.3 Asia Pacific: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	115
10.3.3.1 Asia Pacific: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	116
10.3.4 Asia Pacific: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	116
10.3.5 Asia Pacific: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	117
10.3.6 Asia Pacific: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	117
10.3.7 Asia Pacific: Biosimilars Market, by Country, 2021 & 2028 (%)	117
10.3.7.1 China: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	118
10.3.7.1.1 Overview..	118
10.3.7.1.2 China: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	118
10.3.7.1.3 China: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	119
10.3.7.1.3.1 China: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	119
10.3.7.1.4 China: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	120
10.3.7.1.5 China: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	120
10.3.7.1.6 China Biosimilars Market, by End User, 2019-2028 (US\$ Million)	120
10.3.7.2 Japan: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	121
10.3.7.2.1 Overview..	121
10.3.7.2.2 Japan: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	121
10.3.7.2.3 Japan: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	122
10.3.7.2.3.1 Japan: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	122
10.3.7.2.4 Japan: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	123
10.3.7.2.5 Japan: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	123
10.3.7.2.6 Japan: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	123
10.3.7.3 India: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	124

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

10.3.7.3.1 Overview..	124
10.3.7.3.2 India: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	124
10.3.7.3.3 India: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	125
10.3.7.3.3.1 India: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	125
10.3.7.3.4 India: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	125
10.3.7.3.5 India: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	126
10.3.7.3.6 India: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	126
10.3.7.4 South Korea: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	127
10.3.7.4.1 Overview..	127
10.3.7.4.2 South Korea: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	127
10.3.7.4.3 South Korea: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	127
10.3.7.4.3.1 South Korea: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	128
10.3.7.4.4 South Korea: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	128
10.3.7.4.5 South Korea: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	129
10.3.7.4.6 South Korea: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	129
10.3.7.5 Australia: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	130
10.3.7.5.1 Overview..	130
10.3.7.5.2 Australia: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	130
10.3.7.5.3 Australia: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	130
10.3.7.5.3.1 Australia: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	131
10.3.7.5.4 Australia: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	131
10.3.7.5.5 Australia: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	132
10.3.7.5.6 Australia: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	132
10.3.7.6 Rest of Asia Pacific: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	133
10.3.7.6.1 Overview..	133
10.3.7.6.2 Rest of Asia Pacific: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	133
10.3.7.6.3 Rest of Asia Pacific: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	134
10.3.7.6.3.1 Rest of Asia Pacific: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	134
10.3.7.6.4 Rest of Asia Pacific: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	135
10.3.7.6.5 Rest of Asia Pacific: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	135
10.3.7.6.6 Rest of Asia Pacific: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	135
10.4 Middle East and Africa: Biosimilars Market	137
10.4.1 Overview..	137
10.4.2 Middle East and Africa: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	138
10.4.3 Middle East and Africa: Biosimilar Market, by Disease Indication, 2019-2028 (US\$ Million)	138
10.4.3.1 Middle East and Africa: Biosimilar Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	139
10.4.4 Middle East and Africa: Biosimilar Market, by Drug Class, 2019-2028 (US\$ Million)	139
10.4.5 Middle East and Africa: Biosimilar Market, by Route of Administration, 2019-2028 (US\$ Million)	139
10.4.6 Middle East and Africa: Biosimilar Market, by End User, 2019-2028 (US\$ Million)	140
10.4.7 Middle East and Africa: Biosimilar Market, by Country, 2021 & 2028 (%)	140
10.4.7.1 Saudi Arabia: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	141
10.4.7.1.1 Overview..	141
10.4.7.1.2 Saudi Arabia: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	141
10.4.7.1.3 Saudi Arabia: Biosimilar Market, by Disease Indication, 2019-2028 (US\$ Million)	142
10.4.7.1.3.1 Saudi Arabia: Biosimilar Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	142
10.4.7.1.4 Saudi Arabia: Biosimilar Market, by Drug Class, 2019-2028 (US\$ Million)	142
10.4.7.1.5 Saudi Arabia: Biosimilar Market, by Route of Administration, 2019-2028 (US\$ Million)	143

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

10.4.7.1.6 Saudi Arabia: Biosimilar Market, by End User, 2019-2028 (US\$ Million)	143
10.4.7.2 South Africa: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	144
10.4.7.2.1 South Africa: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	144
10.4.7.2.2 South Africa: Biosimilar Market, by Disease Indication, 2019-2028 (US\$ Million)	145
10.4.7.2.2.1 South Africa: Biosimilar Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	145
10.4.7.2.3 South Africa: Biosimilar Market, by Drug Class, 2019-2028 (US\$ Million)	145
10.4.7.2.4 South Africa: Biosimilar Market, by Route of Administration, 2019-2028 (US\$ Million)	146
10.4.7.2.5 South Africa: Biosimilar Market, by End User, 2019-2028 (US\$ Million)	146
10.4.7.3 UAE: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	147
10.4.7.3.1 UAE: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	147
10.4.7.3.2 UAE: Biosimilar Market, by Disease Indication, 2019-2028 (US\$ Million)	148
10.4.7.3.2.1 UAE: Biosimilar Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	148
10.4.7.3.3 UAE: Biosimilar Market, by Drug Class, 2019-2028 (US\$ Million)	148
10.4.7.3.4 UAE: Biosimilar Market, by Route of Administration, 2019-2028 (US\$ Million)	149
10.4.7.3.5 UAE: Biosimilar Market, by End User, 2019-2028 (US\$ Million)	149
10.4.7.4 Rest of Middle East and Africa: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	150
10.4.7.4.1 Rest of Middle East and Africa: Biosimilar Market - Revenue and Forecast to 2028 (US\$ Million)	150
10.4.7.4.2 Rest of Middle East and Africa: Biosimilar Market, by Disease Indication, 2019-2028 (US\$ Million)	150
10.4.7.4.2.1 Rest of Middle East and Africa: Biosimilar Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	151
10.4.7.4.3 Rest of Middle East and Africa: Biosimilar Market, by Drug Class, 2019-2028 (US\$ Million)	151
10.4.7.4.4 Rest of Middle East and Africa: Biosimilar Market, by Route of Administration, 2019-2028 (US\$ Million)	152
10.4.7.4.5 Rest of Middle East and Africa: Biosimilar Market, by End User, 2019-2028 (US\$ Million)	152
10.5 South & Central America Biosimilars Market	153
10.5.1 Overview..	153
10.5.2 South & Central America: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	153
10.5.3 South & Central America: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	154
10.5.3.1 South & Central America: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	154
10.5.4 South & Central America: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	154
10.5.5 South & Central America: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	155
10.5.6 South & Central America: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	155
10.5.7 South & Central America: Biosimilars Market, by Country, 2021 & 2028 (%)	156
10.5.7.1 Brazil: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	156
10.5.7.1.1 Overview..	156
10.5.7.1.2 Brazil: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	156
10.5.7.1.3 Brazil: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	157
10.5.7.1.3.1 Brazil: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	157
10.5.7.1.4 Brazil: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	157
10.5.7.1.5 Brazil: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	158
10.5.7.1.6 Brazil: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	158
10.5.7.2 Argentina: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	159
10.5.7.2.1 Overview..	159
10.5.7.2.2 Argentina: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	159
10.5.7.2.3 Argentina: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	159
10.5.7.2.3.1 Argentina: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	160
10.5.7.2.4 Argentina: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	160
10.5.7.2.5 Argentina: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	161
10.5.7.2.6 Argentina: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	161

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.5.7.3 Rest of South & Central America: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	162
10.5.7.3.1 Overview..	162
10.5.7.3.2 Rest of South & Central America: Biosimilars Market - Revenue and Forecast to 2028 (US\$ Million)	162
10.5.7.3.3 Rest of South & Central America: Biosimilars Market, by Disease Indication, 2019-2028 (US\$ Million)	163
10.5.7.3.3.1 Rest of South & Central America: Biosimilars Market, by Autoimmune Diseases, 2019-2028 (US\$ Million)	163
10.5.7.3.4 Rest of South & Central America: Biosimilars Market, by Drug Class, 2019-2028 (US\$ Million)	164
10.5.7.3.5 Rest of South & Central America: Biosimilars Market, by Route of Administration, 2019-2028 (US\$ Million)	164
10.5.7.3.6 Rest of South & Central America: Biosimilars Market, by End User, 2019-2028 (US\$ Million)	165
11. Biosimilars Market - Industry Landscape	166
11.1 Overview..	166
11.2 Growth Strategies in the Biosimilars Market	166
11.3 Inorganic Growth Strategies.	167
11.3.1 Overview..	167
11.4 Organic Growth Strategies.	169
11.4.1 Overview..	169
12. Company Profiles	172
12.1 Amgen Inc.	172
12.1.1 Key Facts.	172
12.1.2 Business Description.	172
12.1.3 Products and Services.	172
12.1.4 Financial Overview..	173
12.1.5 SWOT Analysis.	175
12.1.6 Key Developments.	175
12.2 Celltrion Inc.	176
12.2.1 Key Facts.	176
12.2.2 Business Description.	176
12.2.3 Products and Services.	176
12.2.4 Financial Overview..	176
12.2.5 SWOT Analysis.	178
12.2.6 Key Developments.	179
12.3 Sanofi SA.	180
12.3.1 Key Facts.	180
12.3.2 Business Description.	180
12.3.3 Products and Services.	181
12.3.4 Financial Overview..	181
12.3.5 SWOT Analysis.	183
12.3.6 Key Developments.	183
12.4 Biocon Ltd.	184
12.4.1 Key Facts.	184
12.4.2 Business Description.	184
12.4.3 Products and Services.	184
12.4.4 Financial Overview..	185
12.4.5 SWOT Analysis.	186
12.4.6 Key Developments.	187
12.5 Samsung Bioepis Co Ltd.	188
12.5.1 Key Facts.	188
12.5.2 Business Description.	188

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

12.5.3	Products and Services.	188
12.5.4	Financial Overview..	188
12.5.5	SWOT Analysis.	189
12.5.6	Key Developments.	190
12.6	Coherus BioSciences Inc.	191
12.6.1	Key Facts.	191
12.6.2	Business Description.	191
12.6.3	Products and Services.	191
12.6.4	Financial Overview..	191
12.6.5	SWOT Analysis.	193
12.6.6	Key Developments.	194
12.7	Eli Lilly and Co.	195
12.7.1	Key Facts.	195
12.7.2	Business Description.	195
12.7.3	Products and Services.	196
12.7.4	Financial Overview..	196
12.7.5	SWOT Analysis.	198
12.7.6	Key Developments.	198
12.8	Sandoz AG..	199
12.8.1	Key Facts.	199
12.8.2	Business Description.	199
12.8.3	Products and Services.	199
12.8.4	Financial Overview..	199
12.8.5	SWOT Analysis.	200
12.8.6	Key Developments.	201
12.9	Teva Pharmaceutical Industries Ltd.	202
12.9.1	Key Facts.	202
12.9.2	Business Description.	202
12.9.3	Products and Services.	203
12.9.4	Financial Overview..	203
12.9.5	SWOT Analysis.	205
12.9.6	Key Developments.	205
12.10	Pfizer Inc.	206
12.10.1	Key Facts.	206
12.10.2	Business Description.	206
12.10.3	Products and Services.	207
12.10.4	Financial Overview..	207
12.10.5	SWOT Analysis.	209
12.10.6	Key Developments.	209
12.11	Dr. Reddy's Laboratories Ltd.	210
12.11.1	Key Facts.	210
12.11.2	Business Description.	210
12.11.3	Products and Services.	210
12.11.4	Financial Overview..	211
12.11.5	SWOT Analysis.	212
12.11.6	Key Developments.	212
13.	Appendix	214

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

13.1 About The Insight Partners. 214

13.2 Glossary of Terms. 214

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Biosimilars Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)**

Market Report | 2023-02-24 | 217 pages | The Insight Partners

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User Price	\$4550.00
	Site Price	\$6550.00
	Enterprise Price	\$8550.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>